Sustained-release tablets of venlafaxine HCl were designed using a controlled porosity osmotic formulation. This study aimed to develop and test an osmotic pump tablet with controlled porosity containing venlafaxine hydrochloride. Because of its excellent water solubility and near-to-one bioavailability, the antidepressant venlafaxine hydrochloride (VH) is placed in Biopharmaceutical Classifi cation System (BCS) class 1. Its short elimination half-life of 5 hours means that patients rarely take it as directed because they have to take two doses each day to make up for it. As a result, there is a high clinical and economic potential for a VH controlled administration dose form that can increase patient compliance. We looked on the dynamics between pharmacological excipients using FTIR. The core of the tablet was made using wet granulation, and the tablets were then covered. After 24 hours of in vitro testing, the drug’s release profi le was consistent with expectations. It was discovered that the rate of drug release increased with increasing pore former concentration, however, the percentage weight gain of the tablet coating inversely associated with the amount of pore former used. Drug release was investigated in relation to pore past weight development and weight percentage. SEM confi rmed optimised (F7) batch’s micro porous structure.